See more : E-data Corporation (EDTA) Income Statement Analysis – Financial Results
Complete financial analysis of Fusion Antibodies plc (FAB.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Fusion Antibodies plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Computer Modelling Group Ltd. (CMDXF) Income Statement Analysis – Financial Results
- Jinhe Biotechnology CO., LTD. (002688.SZ) Income Statement Analysis – Financial Results
- Toyo Wharf & Warehouse Co., Ltd. (9351.T) Income Statement Analysis – Financial Results
- Nine Dragons Paper (Holdings) Limited (2689.HK) Income Statement Analysis – Financial Results
- EDP – Energias do Brasil S.A. (ENBR3.SA) Income Statement Analysis – Financial Results
Fusion Antibodies plc (FAB.L)
About Fusion Antibodies plc
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.14M | 2.90M | 4.80M | 4.17M | 3.90M | 2.18M | 2.69M | 1.91M | 1.48M | 909.29K | 723.05K | 405.00K |
| Cost of Revenue | 1.40M | 2.70M | 3.08M | 2.86M | 2.74M | 1.38M | 1.21M | 952.46K | 618.06K | 460.44K | 369.27K | 350.47K |
| Gross Profit | -265.00K | 202.00K | 1.72M | 1.31M | 1.15M | 804.00K | 1.48M | 961.50K | 863.21K | 448.85K | 353.77K | 54.52K |
| Gross Profit Ratio | -23.33% | 6.96% | 35.78% | 31.45% | 29.58% | 36.85% | 55.13% | 50.24% | 58.28% | 49.36% | 48.93% | 13.46% |
| Research & Development | 254.00K | 806.00K | 699.00K | 613.00K | 391.00K | 240.00K | 69.00K | 70.00K | 0.00 | 0.00 | 160.94K | 199.92K |
| General & Administrative | 2.25M | 3.05M | 3.03M | 2.74M | 2.26M | 2.40M | 1.40M | 880.64K | 842.63K | 568.64K | 325.46K | 323.48K |
| Selling & Marketing | -474.00K | -822.00K | -679.00K | -668.00K | -389.00K | 0.00 | 2.99K | 0.00 | 0.00 | 0.00 | 20.99K | 32.08K |
| SG&A | 1.77M | 2.23M | 2.35M | 2.08M | 1.88M | 2.40M | 1.41M | 880.64K | 842.63K | 568.64K | 346.44K | 355.56K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -86.41K | 0.00 | -45.67K | -7.10K | -21.00K | 0.00 | 0.00 |
| Operating Expenses | 2.03M | 3.04M | 3.05M | 2.69M | 2.27M | 2.31M | 2.19M | 834.97K | 835.53K | 547.64K | 473.20K | 527.74K |
| Cost & Expenses | 3.42M | 5.73M | 6.13M | 5.54M | 5.01M | 3.69M | 3.40M | 1.79M | 1.45M | 1.01M | 842.47K | 878.21K |
| Interest Income | 3.00K | 3.00K | 1.00K | 3.00K | 6.00K | 12.60K | 819.00 | 615.00 | 496.00 | 1.00 | 1.06K | 427.00 |
| Interest Expense | 5.00K | 4.00K | 9.00K | 18.00K | 20.00K | 4.03K | 4.86K | 615.00 | 496.00 | 665.00 | 1.06K | 427.00 |
| Depreciation & Amortization | 220.00K | 372.00K | 751.00K | 714.00K | 622.00K | 431.22K | 69.63K | 32.99K | 22.24K | 19.44K | 18.33K | 28.47K |
| EBITDA | -2.06M | -2.48M | -573.00K | -532.00K | -431.00K | -1.06M | -636.88K | 288.47K | 49.92K | -79.35K | -101.09K | -444.75K |
| EBITDA Ratio | -181.69% | -84.83% | -12.11% | -15.97% | -12.63% | -48.79% | 4.91% | 8.33% | 3.37% | -8.73% | -13.98% | -109.82% |
| Operating Income | -2.29M | -2.83M | -1.33M | -1.38M | -1.11M | -1.51M | 62.39K | 126.53K | 27.69K | -98.79K | -119.43K | -473.22K |
| Operating Income Ratio | -201.41% | -97.66% | -27.76% | -33.11% | -28.60% | -69.14% | 2.32% | 6.61% | 1.87% | -10.86% | -16.52% | -116.84% |
| Total Other Income/Expenses | -1.00K | -1.00K | -8.00K | -15.00K | -14.00K | 9.00K | -773.76K | -615.00 | -496.00 | -664.00 | -1.06K | -427.00 |
| Income Before Tax | -2.29M | -2.86M | -1.33M | -1.26M | -1.07M | -1.50M | -711.36K | 125.92K | 27.19K | -99.45K | -120.48K | -473.65K |
| Income Before Tax Ratio | -201.50% | -98.55% | -27.78% | -30.35% | -27.55% | -68.74% | -26.44% | 6.58% | 1.84% | -10.94% | -16.66% | -116.95% |
| Income Tax Expense | -63.00K | -263.00K | -133.00K | 1.64M | -376.00K | -235.49K | 11.42K | 5.96K | -1.13M | -14.34K | 6.95K | 4.91K |
| Net Income | -2.23M | -2.60M | -1.20M | -2.90M | -697.00K | -1.26M | -699.94K | 119.95K | 1.15M | -85.11K | -113.54K | -468.74K |
| Net Income Ratio | -195.95% | -89.49% | -25.01% | -69.60% | -17.89% | -57.95% | -26.01% | 6.27% | 77.91% | -9.36% | -15.70% | -115.74% |
| EPS | -0.04 | -0.10 | -0.05 | -0.11 | -0.03 | -0.06 | -0.04 | 0.01 | 0.05 | 0.00 | -0.01 | -0.02 |
| EPS Diluted | -0.04 | -0.10 | -0.05 | -0.11 | -0.03 | -0.06 | -0.04 | 0.01 | 0.05 | 0.00 | -0.01 | -0.02 |
| Weighted Avg Shares Out | 55.56M | 26.01M | 25.95M | 25.46M | 22.09M | 22.09M | 16.12M | 22.09M | 22.09M | 22.09M | 22.09M | 22.09M |
| Weighted Avg Shares Out (Dil) | 55.56M | 26.01M | 25.95M | 25.46M | 22.09M | 22.09M | 16.12M | 22.09M | 22.09M | 22.09M | 22.09M | 22.09M |
Source: https://incomestatements.info
Category: Stock Reports